Skip to main content
Download PDF

Modulating arousal to overcome gait impairments in Parkinson’s disease: how the noradrenergic system may act as a double-edged sword

Translational Neurodegeneration volume 12, Article number: 15 (2023) Cite this article

Abstract

In stressful or anxiety-provoking situations, most people with Parkinson’s disease (PD) experience a general worsening of motor symptoms, including their gait impairments. However, a proportion of patients actually report benefits from experiencing—or even purposely inducing—stressful or high-arousal situations. Using data from a large-scale international survey study among 4324 people with PD and gait impairments within the online Fox Insight (USA) and ParkinsonNEXT (NL) cohorts, we demonstrate that individuals with PD deploy an array of mental state alteration strategies to cope with their gait impairment. Crucially, these strategies differ along an axis of arousal—some act to heighten, whereas others diminish, overall sympathetic tone. Together, our observations suggest that arousal may act as a double-edged sword for gait control in PD. We propose a theoretical, neurobiological framework to explain why heightened arousal can have detrimental effects on the occurrence and severity of gait impairments in some individuals, while alleviating them in others. Specifically, we postulate that this seemingly contradictory phenomenon is explained by the inherent features of the ascending arousal system: namely, that arousal is related to task performance by an inverted u-shaped curve (the so-called Yerkes and Dodson relationship). We propose that the noradrenergic locus coeruleus plays an important role in modulating PD symptom severity and expression, by regulating arousal and by mediating network-level functional integration across the brain. The ability of the locus coeruleus to facilitate dynamic ‘cross-talk’ between distinct, otherwise largely segregated brain regions may facilitate the necessary cerebral compensation for gait impairments in PD. In the presence of suboptimal arousal, compensatory networks may be too segregated to allow for adequate compensation. Conversely, with supraoptimal arousal, increased cross-talk between competing inputs of these complementary networks may emerge and become dysfunctional. Because the locus coeruleus degenerates with disease progression, finetuning of this delicate balance becomes increasingly difficult, heightening the need for mental strategies to self-modulate arousal and facilitate shifting from a sub- or supraoptimal state of arousal to improve gait performance. Recognition of this underlying mechanism emphasises the importance of PD-specific rehabilitation strategies to alleviate gait disability.

Introduction

A person’s mental state is an important intrinsic factor affecting the expression of a variety of neurological motor symptoms, from dystonia to hemiparesis after stroke [1]. Parkinson’s disease (PD) is a prototypical example highlighting this captivating interaction, where alterations in the mental state often lead to immediate observable changes in motor symptoms. While tremor is the prime example of a PD motor feature that typically worsens during stressful situations and with increased cognitive load [2,3,4,5,6], other motor symptoms, such as gait impairments, are also often aggravated by stress and anxiety [6,7,8]. Gait impairments in PD comprise both continuously present deficits (e.g., reduced step length and height, reduced gait speed, and increased gait variability) as well as episodic deficits (i.e., festination and freezing of gait) [9]. The detrimental effect of stressful, anxiety-inducing situations on the occurrence and severity of freezing of gait episodes has been particularly well-established [10,11,12,13,14,15,16]. Unsurprisingly, many people with PD and gait impairment use strategies to counteract stress or anxiety, in an effort to improve their walking ability. Of these approaches, mindfulness-based interventions have received the most attention in recent years [17,18,19,20].

Paradoxically, in contrast to this negative impact on gait, some PD patients seem to actually benefit from experiencing—or even purposely inducing—stressful situations. The most extreme form is the well-known phenomenon of ‘kinesia paradoxa’: a sudden, transient ability to perform a task that a person was previously unable to complete, often in the context of grave, life-threatening situations [21, 22]. A classic case example was offered by a group of 14 institutionalized Italian patients with advanced PD, who demonstrated an extraordinary motor improvement during the L’Aquila earthquake of 2009 [23]. All of them were able to escape unaided from the collapsing nursing home, despite usually requiring assistance during daily activities because of severe gait difficulties and postural instability. While kinesia paradoxa may well be an entity on its own, it has been hypothesized that gait improvement under more mundane circumstances that increase motivation may share a similar underlying mechanism, namely a shift to optimally heighten arousal [24]. These common clinical observations raise an interesting question—how is it that heightened arousal can augment symptoms in some individuals, while alleviating their severity in others?

Here, we suggest that this paradox is related to inherent features of the ascending arousal system. Over a century ago, psychologists Yerkes and Dodson demonstrated that task performance is related to arousal (Fig. 1) [25]. The inverted u-shaped curve illustrates that task performance improves with increasing arousal, until an optimum is reached. When the optimal level of arousal is surpassed, performance declines again as arousal increases further. Depending on where you are situated on this curve, a change in arousal could therefore be either beneficial or detrimental to performance of the task at hand. Translating this notion to gait impairments in PD, on the left-hand side of this curve (i.e., with suboptimal arousal), gait might be ameliorated by strategies that increase arousal levels. Conversely, on the right-hand side of the curve (i.e., with supraoptimal arousal) gait might benefit from strategies that decrease arousal.

Fig. 1
figure 1

The relationship between arousal and task performance, related to the effects of compensatory strategies targeting arousal. Based on Yerkes and Dodson [25]. (a) Suboptimal state of arousal. In the case of suboptimal arousal, a person with Parkinson’s disease (PD) would likely benefit from applying a compensation strategy that aims to increase the level of arousal (e.g., by adding an element of time pressure), in order to optimize task performance. (b) Optimal state of arousal. In the case of optimal arousal, optimal task performance is expected. (c) Supraoptimal state of arousal. In the case of supraoptimal arousal, a person with PD would likely benefit from applying a compensation strategy that aims to reduce the level of arousal (e.g., by employing relaxation techniques), in order to optimize task performance

Full size image

Compensation strategies tapping into this mechanism of modulating arousal levels are typically attributed to a category entitled ‘Altering the Mental State’. This is one of seven major categories of compensation strategies for gait impairment, based on a comprehensive review of several hundred videos of persons with PD who spontaneously ‘invented’ strategies to improve their gait [24]. The ‘Altering the Mental State’ category has thus far received relatively little attention, certainly when compared to other categories such as external or internal cueing [26]. For obvious reasons, it is not recommended to implement life-threatening situations in daily life to improve gait impairment. However, reports on ‘everyday’ variants of less drastic arousal strategies are scarce. Indeed, PD healthcare professionals rarely apply strategies from the ‘Altering the Mental State’ category in their clinical practice [27], even though persons with PD find it a valuable way to cope with their gait impairments in daily life [28]. Furthermore, the mechanisms underlying this category of strategies remain poorly understood.

Here, we introduce a novel theoretical framework regarding the potential underlying mechanisms of modulating one’s arousal to optimize gait performance in PD. To this aim, we first present an array of ready-to-use ‘Altering the Mental State’ strategies for gait impairment, informed by data from a large-scale international survey study among over 4000 persons with PD and gait impairments [28], illustrating our hypothesis that the noradrenergic system may act as a double-edged sword in PD gait control.

Methods

Study population

The present study is a secondary analysis of a web-based survey that was distributed among 6700 participants within the Fox Insight cohort (USA), as well as 1573 Dutch participants within the ParkinsonNEXT cohort (NL) [28]. Fox Insight is a longitudinal, virtual, patient-centered observational study on PD led by the Michael J Fox Foundation. Data used in the preparation of this article were obtained from the Fox Insight database on June 1st 2020. For up-to-date information on the study, visit https://foxinsights-info.michaeljfox.org/insight/explore/insight.jsp. ParkinsonNEXT (http://www.parkinsonnext.nl) is an online platform that aims to unite patients, researchers and clinicians wanting to contribute to research and innovation in PD or parkinsonism. The online survey was accessible from March to June 2020. Respondents above the age of 18 years with a self-reported diagnosis of PD and self-reported disabling gait impairments were included in the analyses.

Survey

Details on the design and content of the original survey, which consisted of three parts, have been previously reported [28]. We will reiterate the elements relevant to the present study. The survey addressed seven main categories of compensation strategies, including ‘Altering the Mental State’ [24]. This category was explained and illustrated by several practical examples. Participants were then queried whether they had ever applied a strategy belonging to the ‘Altering the Mental State’ category, and—if so—what specific strategy they had used (free-text entry).

Data processing and analysis

Based on the free-text entries that respondents had provided, data were verified and manually corrected by two independent researchers, to ensure that all recorded compensation strategies were completed under the appropriate corresponding category. ‘Altering the Mental State’ strategies were then classified into being either ‘strategies that reduce arousal’ (e.g., relaxation techniques, mindfulness) or ‘strategies that increase arousal’ (e.g., experiencing high-pressure situations, getting angry). Strategies that were difficult to intuitively place into one of two categories were discussed among all study investigators until consensus was reached. All (descriptive) statistical analyses were performed in IBM SPSS 25 (SPSS, Inc., Chicago, IL). Independent t-tests and chi-square tests were performed to assess group differences in demographic characteristics. Values of P < 0.05 were considered to be statistically significant.

Ethical approval

The study was approved by the Institutional Review Board of the Radboud University Medical Center in Nijmegen, the Netherlands (Ref: 2019-5737). Written informed consent was not necessary for this work.

Results

Study population

In total, 5832 respondents successfully completed the questionnaire. We collected 4987 responses via Fox Insight (response rate: 74.4%), and 845 via ParkinsonNEXT (response rate: 53.7%), of which 1508 persons were excluded as they did not experience disabling gait impairments. Characteristics of the remaining final sample of 4324 respondents, of whom 1343 (31.1%) reported to have ever used ‘Altering the Mental State’ strategies, are presented in Table 1. Notably, the sample of respondents who used ‘Altering the Mental State’ strategies comprised relatively more women (47.4% vs 43.6%, P = 0.022), and the prevalence of freezing of gait (49.2% vs 41.6%, P < 0.001) and falls (58.4% vs 49.7%, P < 0.001) was higher in this group compared to the sample of respondents who did not use ‘Altering the Mental State’ strategies.

Table 1 Respondent characteristics
Full size table

‘Altering the Mental State’ strategies

As expected, we were able to identify a clear divide between those strategies that seemed to reduce arousal (i.e., through reducing stress or anxiety) at one end of the spectrum versus those strategies aimed at purposefully increasing arousal (i.e., through increasing stress levels or motivation) at the other end. An overview of the specific ‘Altering the Mental State’ strategies that the 1343 respondents employed to overcome their gait impairments in daily life is presented in Table 2. Some of the examples represent strategies that include a clear element of ‘Altering the Mental State’ in combination with elements of other known categories of compensation (e.g., motor imagery or internal cueing) [24].

Table 2 Reported ‘Altering the Mental State’ strategies for gait impairments in Parkinson’s disease
Full size table

Strategies that reduce arousal

Among all reported ‘Altering the Mental State’ strategies, strategies to reduce arousal were most common (76.5%). They most frequently entailed: breathing exercises (n = 593); mindfulness and meditation (n = 522); stretching before walking (n = 190); and praying (n = 31). Respondents reported many creative ways to achieve a sense of general relaxation to improve gait before going out for a walk, ranging from listening to soothing music to playing a game of digital solitaire before going anywhere: “I recite the 7 countries of Central America and the 13 countries of South America, this relaxes me. I’m learning Europe next”. Others reported to specifically focus on tackling negative emotions or cognitions surrounding gait right before or during walking: "I have always been a believer in the individual’s ability to get more from their mental attitude than they otherwise do. I focus on the mental reasons I freeze, such as a fear of falling, and tell myself quite profoundly that it is only a fear and I must, simply must overcome it”. Some respondents reported to walk better when they feel like they are well-prepared and have a back-up plan in case gait difficulties (e.g., freezing of gait) emerge: “I always take a ‘test walk’ in the family room before going outside”; “I always carry around a cane, even though I do not actually use it for support. Just having it with me gives me more confidence to walk, as I will have something to help me in case I freeze. I feel like I freeze more often when I do not bring the cane with me.”

Strategies that increase arousal

Strategies that seemed to purposefully increase arousal (23.5%) most often comprised: getting oneself angry or ‘pumped’ (n = 59) and forceful (often abusive) self-talk to motivate oneself to move (n = 86). Multiple respondents mentioned that they had noticed a marked improvement in their ability to move when they experienced stress or ‘a rush of adrenalin’: “When my adrenaline is high, I am suddenly able to perform actions that I could not do before”; “Stress increases my focus and the fear factor makes me perform and walk better”. Some indicated that they would simulate this feeling by getting themselves very angry: “When I get very angry I feel my power increasing, it even enables me to run”; or by challenging themselves: “If I imagine a twisty trail with rocks and roots and other obstacles while walking, I'm more alert and I walk better”. Another respondent even reported to purposefully inflict pain on herself to achieve an improvement in gait: “I find that if I slap my right wrist really hard with my left hand, that for the next hour or more, my mind is confused and will concentrate on the wrist pain and forget the leg issues”.

In addition to these examples of inducing arousal with negative valence, high arousal states with positive valence were reported to improve gait performance in a similar matter. Specifically, respondents mentioned to benefit from inducing a state of ‘flow’ (a state of being fully absorpted by a task, established by an optimal match between the person’s skills and the task challenges [30]) through doing something they enjoyed: “After an intense programming session on my computer, I found myself being ‘freed’ of my Parkinson’s disease for several hours”. Physical exercise before walking was also frequently reported to improve overall gait performance. Physical activity is a special example of ‘Altering the Mental State’ strategies, as it can be employed to facilitate general relaxation with low-intensity exercises (i.e., a decrease in arousal), as well as induce general excitement with higher intensity exercises (i.e., an increase in arousal). While some respondents reported to prefer to relax through yoga or tai chi exercises, others preferred to exercise in order to ‘kickstart’ themselves, for example by performing a quick set of push-ups before going out for a walk.

Subgroup characterization

A characterization of the subgroups of respondents based on the type of strategies they had ever tried is presented in Table 3. Most respondents had only ever tried strategies aimed at reducing arousal (83.5%). Notably, the subgroup of respondents that had used strategies to increase arousal comprised more men (65.2% vs 52.6%) and more individuals with freezing of gait (58.7% vs 43.9%) compared to the subgroup of respondents that had used strategies to reduce arousal.

Table 3 Subgroup characteristics
Full size table

Discussion

Here, we present an overview of ‘Altering the Mental State’ strategies that persons with PD applied in an effort to overcome their gait impairments in daily life. Approximately one in three patients with gait impairments reported altering their mental state as a compensatory strategy. While most persons with PD reported to have used strategies that reduced arousal (e.g., by diminishing stress, or promoting general relaxation), a smaller group actually reported to have purposely increased their arousal to improve gait. We will next elaborate on our theoretical framework regarding the potential underlying mechanisms and address the clinical implications of self-modulating arousal to optimize gait performance in PD.

From a neurobiological perspective, the concept of fine-tuning one’s arousal level to optimizing one’s ability to compensate for gait impairments in PD is tightly connected to the functions of the locus coeruleus. The locus coeruleus is a small nucleus located in the posterior area of the rostral pons, and represents the primary source of noradrenaline for the central nervous system [31]. Its widespread noradrenergic projections modulate cortical, subcortical, cerebellar, brainstem and spinal cord circuits, which makes it well suited to rapidly and globally modulate brain function in response to changes in the environment (e.g., stressful stimuli) [32]. Moreover, locus coeruleus noradrenaline contributes to the reconfiguration of functional communication between distributed brain regions [33]. It is part of the ascending arousal pathway, and plays a major role in attentional and arousal response to threat [34]. Indeed, locus coeruleus activity displays an inverted u-shaped relationship with task performance, in accordance with Yerkes-Dodson’s law [35, 36]. Therefore, changes in the firing rate of the locus coeruleus may facilitate a shift in arousal that promotes optimal performance on the task at hand (Fig. 1). The neuromodulatory impact of the locus coeruleus on the central nervous system is classically compared to tuning the volume of a radio, even though its precise adaptive role is more complex and dynamic, and more appropriately analogous to the bowing of a violin [37]. Much like the effect that a bow has on the strings of a violin, the locus coeruleus changes the way the ‘notes’ are expressed (e.g., their volume or tone quality) without affecting the specific string of notes in itself, in order to shape complex neuronal melodies [37]. Increased activity of the locus coeruleus (i.e., turning up the volume) increases the strength of functional interactions between brain regions that are otherwise largely segregated [38, 39], as noradrenaline elicits changes in the internal milieu of target cells to alter their ‘neural gain’ (i.e., their excitability and receptivity to incoming signals) [40]. By mediating this increased network-level integration across the brain, the locus coeruleus can facilitate dynamic ‘cross-talk’ between different regions across the cortex and subcortex that are critical for higher-order functions [41, 42]. This functional integration is of particular importance in gait control in PD.

The pathophysiology underlying gait impairments in PD is complex and presumably involves dysfunction of multiple cortical and subcortical components. Gait partly depends on a basic ‘locomotor network’, involving spinal central pattern generators, brainstem mesencephalic and cerebellar locomotor regions, along with the corticostriatal input projecting to the primary motor cortex [43, 44]. In addition, distributed cortical areas, particularly the frontoparietal and supplementary motor areas, are normally involved in the adjustment and adaptation of walking [45]. During walking in an automated manner (i.e., without consciously paying attention to it), persons with PD typically have difficulties recruiting these cortical motor areas [46]. Adequate gait control therefore not only relies on the integrity and function of corticostriatal motor loops, but on compensatory input from cognitive, sensory and limbic systems as well (Fig. 2) [47,48,49,50]. Reinforcing the integration of these different neural networks may consequently facilitate optimal compensation for the PD-related loss of function in the motor circuitries. When locus coeruleus activity is too low (i.e., suboptimal arousal), the different compensatory networks may be too segregated to allow for adequate compensation of motor impairments. Overactivation of the locus coeruleus (i.e., supraoptimal arousal), on the other hand, may lead to a situation that allows for an element of increased, dysfunctional ‘cross-talk’ between competing inputs of these complementary networks [51]. In PD specifically, this has been associated with detrimental effects on motor function, particularly the occurrence of anxiety-induced freezing of gait [52,53,54]. Unfortunately, the ability to adaptively employ the locus coeruleus to optimally modulate the interaction of compensatory networks may be affected by the profound degeneration of the nucleus in PD, and this is compounded by dysfunction of cortical regions in charge of regulating arousal. Whilst well-established, this loss of noradrenergic neurons (ranging 20%–90% in PD patients [55, 56]) has been relatively neglected [57], even though it both precedes the onset and exceeds the extent of the hallmark loss of dopaminergic neurons in the substantia nigra pars compacta [58,59,60]. The application of ‘Altering the Mental State’ strategies to modulate arousal may therefore be necessary to facilitate shifts from sub- or supraoptimal states of arousal to optimize gait performance in PD.

Fig. 2
figure 2

How modulating arousal may contribute to optimal gait performance in Parkinson’s disease (PD). a Healthy persons. In healthy persons, the primary automatic mode of motor control is intact. Different brain networks are largely segregated, as there is (usually) no need for compensatory input to achieve optimal gait control. b  PD—Suboptimal arousal. Impaired function of the corticostriatal motor network cannot be optimally compensated for by complementary input from other brain networks, as these networks remain largely segregated in this suboptimal state of arousal. c  PD—Optimal arousal. Impaired function of the corticostriatal motor network can be optimally compensated for by complementary input from other brain networks, as these networks are optimally integrated in this optimal state of arousal. d  PD—Supraoptimal arousal. Impaired function of the corticostriatal motor network cannot be optimally compensated for by complementary—but now competing—input from other brain networks, as these networks are engaged in dysfunctionally increased ‘cross-talk’ in this supraoptimal state of arousal. Green circle: intact corticostriatal motor network; Dashed green circle: impaired corticostriatal motor network; Yellow circle: sensory network; Purple circle: limbic network; Blue circle; cognitive network. Black double-sided triangle arrows represent a simplified schematic illustration of the functional integration between the different brain regions (which is presumably much more complex than depicted); Dashed arrows indicate the impaired function of the primary motor circuitry in PD; Thickness of the dark-grey equilateral barb arrows represents the neuromodulatory activity of the locus coeruleus (depicted here in the rostral pons as a small dark-grey ellipse). Figure inspired by Gilat et al. [48]

Full size image

Importantly, the underpinnings of these strategies presumably do not only involve noradrenaline, but other neurotransmitters such as dopamine and serotonin as well [61]. The classic parallel model suggesting a direct correlation between changes in a single neurochemical system and a distinctive deficit is likely to be too simplistic. Rather, a convergent biochemical model in which the complex interactions between the different monoaminergic systems are taken into account would be more appropriate [62]. For example, the concept of reaching a “flow state”, which respondents reported to be helpful in ameliorating gait, illustrates that striking the right balance between motivation (dopamine) and arousal (noradrenaline) can lead to optimized behavior [63, 64]. Arousal levels are also influenced by a multitude of both internal and external factors (e.g., one’s present emotions or physical environment). Even the presence of gait impairments in itself is likely to influence arousal levels in people with PD: it introduces  a vicious cycle of supraoptimal arousal due to anxiety related to falling, in turn leading to aggravated gait impairment, which further increases the fear of falling. However, while a person’s ‘baseline’ position on the curve is likely to be partly trait-dependent (e.g., a chronic state of supraoptimal arousal in those with generalized anxiety or a debilitating fear of falling), it would presumably be predominantly dependent on the task, environment and context at hand (e.g., a sudden increase in arousal when a doorbell rings). In light of this, it is unsurprising that a proportion of respondents reported to have used both types of ‘Altering the Mental State’ strategies in daily life. One can imagine that depending on the situation at hand, the state of arousal—and with that the appropriate type of strategy—may vary. Furthermore, depending on the complexity of the (gait) task at hand, the optimal level of arousal (i.e., the shape of the curve) could vary significantly across tasks [25, 65, 66]. These factors combined may make it particularly difficult to employ pharmacological interventions targeting the noradrenergic system as an add-on to dopaminergic medication to improve gait performance in persons with PD [67,68,69,70]. Any medication targeting the noradrenergic system would potentially impact the trait-dependent ‘baseline’ arousal level, rather than enabling the necessary dynamic adaptation in arousal that might be required over the course of the day. An advantage of the application of non-pharmacological compensation strategies is that it allows for such dynamic approaches that are tailored to the specific personal needs of individual patients under everchanging circumstances. Future studies could investigate whether a more personalized approach to the use of pharmacological agents targeting arousal could be beneficial in selected groups of patients (e.g., those with particularly high or low trait-dependent anxiety levels as measured by existing scales like the State-Trait Anxiety Inventory). For example, if one occupies a highly aroused state the majority of their day, could ‘resetting’ their baseline arousal level help shift them to occupy an optimal part of the curve for a greater proportion of their daily activities? Quantifying baseline levels of locus coeruleus activity using techniques such as neuromelanin-sensitive MRI [71, 72] may hold promise to stratify patients into clinical trials according to their level of noradrenergic (dys)function [73].

The survey data that we used to support our hypothesis rely on the self-reported presence of a PD diagnosis, presence of gait impairment, and the efficacy of the applied mental strategies. The potential presence of selection bias, given the selected and rather proactive subpopulation of PD patients that is typically involved in online cohorts, must also be taken into account when interpreting the survey data. However, these data were merely used to probe the presence of examples of strategies at two ends of the arousal spectrum, rather than to provide an accurate percentage of the prevalence of specific strategies. Nevertheless, future clinical trials are necessary to objectively quantify the efficacy of ‘Altering the Mental State’ strategies in improving gait performance in PD. In conjunction, measuring the effect of applying these strategies on physiological markers of arousal (e.g., measured by skin conductance, heart rate, pupil diameter) would help establish the plausibility of our proposed neurobiological framework. Lastly, looking into specific patient characteristics that may be associated with the efficacy of either arousal-reducing (e.g., high levels of trait anxiety) or arousal-increasing strategies (e.g., high levels of apathy or anhedonia) will be essential to eventually work towards a more personalized approach to the use of these non-pharmacological strategies in clinical practice [74]. Indeed, a subgroup characterization of the present cohort revealed that women less frequently reported to have used strategies to increase arousal, which may be a reflection of the higher prevalence of anxiety among women with PD [75].

Conclusion

Our theoretical framework proposing a central role for the locus coeruleus in facilitating optimal compensation to address gait impairments provides future opportunities to investigate the control of gait, as well as guiding both targeted pharmacological (e.g., tailored use of noradrenergic agents as an add-on to dopaminergic medication in selected PD patients) and non-pharmacological therapies (e.g., a training program on ‘Altering the Mental State’ strategies for persons with PD). It is also possible that the impaired modulation of arousal arising from the dysfunction of the locus coeruleus may have consequences that extend beyond gait and could play a critical role in PD tremor, ‘wearing off’ periods, or other key symptoms that have been demonstrated to be significantly affected by one’s level of arousal (particularly in the context of stress or anxiety) [6]. Future work is necessary to validate this conceptual framework, quantify the efficacy of ‘Altering the Mental State’ strategies, and further crystallize the potential involvement of the noradrenergic system in optimizing motor performance in PD.

Availability of data materials

All individual data collected through the Fox Insight online clinical study are available on the Fox Insight database (https://foxinsight-info.michaeljfox.org/insight/explore/insight.jsp). Qualified researchers, interested in PD or related research, can access Fox Insight data upon account registration, completion of a Data Use Agreement (DUA), acknowledgement of the study publication policy, and review by the Data and Publications Committee. Other data related to the present work are available upon request to the corresponding author.

Abbreviations

PD:

Parkinson’s disease

References

  1. Berlot R, Rothwell JC, Bhatia KP, Kojovic M. Variability of movement disorders: the influence of sensation, action, cognition, and emotions. Mov Disord. 2021;36(3):581–93.

    Article  PubMed  Google Scholar 

  2. Lee HJ, Lee WW, Kim SK, Park H, Jeon HS, Kim HB, et al. Tremor frequency characteristics in Parkinson’s disease under resting-state and stress-state conditions. J Neurol Sci. 2016;362:272–7.

    Article  PubMed  Google Scholar 

  3. Blakemore RL, MacAskill MR, Shoorangiz R, Anderson TJ. Stress-evoking emotional stimuli exaggerate deficits in motor function in Parkinson’s disease. Neuropsychologia. 2018;112:66–76.

    Article  CAS  PubMed  Google Scholar 

  4. Dirkx MF, Zach H, van Nuland AJ, Bloem BR, Toni I, Helmich RC. Cognitive load amplifies Parkinson’s tremor through excitatory network influences onto the thalamus. Brain. 2020;143(5):1498–511.

    Article  PubMed  Google Scholar 

  5. Zach H, Dirkx MF, Pasman JW, Bloem BR, Helmich RC. Cognitive stress reduces the effect of levodopa on Parkinson’s resting tremor. CNS Neurosci Ther. 2017;23(3):209–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. van der Heide A, Speckens AEM, Meinders MJ, Rosenthal LS, Bloem BR, Helmich RC. Stress and mindfulness in Parkinson’s disease—a survey in 5000 patients. NPJ Parkinson’s Dis. 2021;7(1):7.

    Article  Google Scholar 

  7. Ehgoetz Martens KA, Peterson DS, Almeida QJ, Lewis SJG, Hausdorff JM, Nieuwboer A. Behavioural manifestations and associated non-motor features of freezing of gait: a narrative review and theoretical framework. Neurosci Biobehav Rev. 2020;116:350–64.

    Article  PubMed  Google Scholar 

  8. Ehgoetz Martens KA, Ellard CG, Almeida QJ. Anxiety-provoked gait changes are selectively dopa-responsive in Parkinson’s disease. Eur J Neurosci. 2015;42(4):2028–35.

    Article  PubMed  Google Scholar 

  9. Mirelman A, Bonato P, Camicioli R, Ellis TD, Giladi N, Hamilton JL, et al. Gait impairments in Parkinson’s disease. Lancet Neurol. 2019;18(7):697–708.

    Article  PubMed  Google Scholar 

  10. Ehgoetz Martens KA, Ellard CG, Almeida QJ. Does anxiety cause freezing of gait in Parkinson’s disease? PLoS One. 2014;9(9):e106561.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Ehgoetz Martens KA, Hall JM, Gilat M, Georgiades MJ, Walton CC, Lewis SJG. Anxiety and freezing of gait: a new perspective for early intervention. Mov Disord. 2016;31(Supplement 2):S100.

    Google Scholar 

  12. Ehgoetz Martens KA, Lukasik EL, Georgiades MJ, Gilat M, Hall JM, Walton CC, et al. Predicting the onset of freezing of gait: a longitudinal study. Mov Disord. 2018;33(1):128–35.

    Article  PubMed  Google Scholar 

  13. Economou K, Quek D, MacDougall H, Lewis SJG, Ehgoetz Martens KA. Heart rate changes prior to freezing of gait episodes are related to anxiety. J Parkinsons Dis. 2021;11(1):271–82.

    Article  PubMed  Google Scholar 

  14. Lagravinese G, Pelosin E, Bonassi G, Carbone F, Abbruzzese G, Avanzino L. Gait initiation is influenced by emotion processing in Parkinson’s disease patients with freezing. Mov Disord. 2018;33(4):609–17.

    Article  PubMed  Google Scholar 

  15. Lieberman A. Are freezing of gait (FOG) and panic related? J Neurol Sci. 2006;248(1–2):219–22.

    Article  PubMed  Google Scholar 

  16. Macht M, Kaussner Y, Moller JC, Stiasny-Kolster K, Eggert KM, Kruger HP, et al. Predictors of freezing in Parkinson’s disease: a survey of 6,620 patients. Mov Disord. 2007;22(7):953–6.

    Article  PubMed  Google Scholar 

  17. Kwok JYY, Kwan JCY, Auyeung M, Mok VCT, Lau CKY, Choi KC, et al. Effects of mindfulness yoga vs stretching and resistance training exercises on anxiety and depression for people with Parkinson disease: a randomized clinical trial. JAMA Neurol. 2019;76(7):755–63.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Dissanayaka NN, Idu Jion F, Pachana NA, O’Sullivan JD, Marsh R, Byrne GJ, et al. Mindfulness for motor and nonmotor dysfunctions in Parkinson’s disease. Parkinsons Dis. 2016;2016:7109052.

    PubMed  PubMed Central  Google Scholar 

  19. Advocat J, Enticott J, Vandenberg B, Hassed C, Hester J, Russell G. The effects of a mindfulness-based lifestyle program for adults with Parkinson’s disease: a mixed methods, wait list controlled randomised control study. BMC Neurol. 2016;16:166.

    Article  PubMed  PubMed Central  Google Scholar 

  20. van der Heide A, Meinders MJ, Speckens AEM, Peerbolte TF, Bloem BR, Helmich RC. Stress and mindfulness in Parkinson’s disease: clinical effects and potential underlying mechanisms. Mov Disord. 2021;36(1):64–70.

    Article  PubMed  Google Scholar 

  21. Schlesinger I, Erikh I, Yarnitsky D. Paradoxical kinesia at war. Mov Disord. 2007;22(16):2394–7.

    Article  PubMed  Google Scholar 

  22. Duysens J, Nonnekes J. Parkinson’s kinesia paradoxa is not a paradox. Mov Disord. 2021;36(5):1115–8.

    Article  PubMed  Google Scholar 

  23. Bonanni L, Thomas A, Anzellotti F, Monaco D, Ciccocioppo F, Varanese S, et al. Paradoxical kinesia in parkinsonian patients surviving earthquake. Mov Disord. 2010;2:S361.

    Google Scholar 

  24. Nonnekes J, Ruzicka E, Nieuwboer A, Hallett M, Fasano A, Bloem BR. Compensation strategies for gait impairments in Parkinson disease: a review. JAMA Neurol. 2019;76(6):718–25.

    Article  PubMed  Google Scholar 

  25. Yerkes RM, Dodson JD. The relation of strength of stimulus to rapidity of habit-formation. J Comp Neurol Psychol. 1908;18(5):459–82.

    Article  Google Scholar 

  26. Nieuwboer A, Kwakkel G, Rochester L, Jones D, van Wegen E, Willems AM, et al. Cueing training in the home improves gait-related mobility in Parkinson’s disease: the RESCUE trial. J Neurol Neurosurg Psychiatry. 2007;78(2):134–40.

    Article  CAS  PubMed  Google Scholar 

  27. Tosserams A, Nijkrake MJ, Sturkenboom I, Bloem BR, Nonnekes J. Perceptions of compensation strategies for gait impairments in Parkinson’s disease: a survey among 320 healthcare professionals. J Parkinsons Dis. 2020;10(4):1775–8.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Tosserams A, Wit L, Sturkenboom I, Nijkrake MJ, Bloem BR, Nonnekes J. Perception and use of compensation strategies for gait impairment by persons with Parkinson disease. Neurology. 2021;97(14):e1404–12.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Nieuwboer A, Rochester L, Herman T, Vandenberghe W, Emil GE, Thomaes T, et al. Reliability of the new freezing of gait questionnaire: agreement between patients with Parkinson’s disease and their carers. Gait Posture. 2009;30(4):459–63.

    Article  PubMed  Google Scholar 

  30. Keller J. The flow experience revisited: the influence of skills-demands-compatibility on experiential and physiological indicators. In: Harmat L, Ørsted Andersen F, Ullén F, Wright J, Sadlo G, editors. Flow experience: empirical research and applications. Cham: Springer; 2016. p. 351–74.

    Chapter  Google Scholar 

  31. Breton-Provencher V, Sur M. Active control of arousal by a locus coeruleus GABAergic circuit. Nat Neurosci. 2019;22(2):218–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Totah NK, Neves RM, Panzeri S, Logothetis NK, Eschenko O. The locus coeruleus is a complex and differentiated neuromodulatory system. Neuron. 2018;99(5):1055–68.

    Article  CAS  PubMed  Google Scholar 

  33. Zhou C, Guo T, Bai X, Wu J, Gao T, Guan X, et al. Locus coeruleus degeneration is associated with disorganized functional topology in Parkinson’s disease. NeuroImage Clin. 2021;32: 102873.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Samuels ER, Szabadi E. Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans. Curr Neuropharmacol. 2008;6(3):254–85.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. Aston-Jones G, Cohen JD. Adaptive gain and the role of the locus coeruleus-norepinephrine system in optimal performance. J Comp Neurol. 2005;493(1):99–110.

    Article  CAS  PubMed  Google Scholar 

  36. Aston-Jones G, Cohen JD. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu Rev Neurosci. 2005;28:403–50.

    Article  CAS  PubMed  Google Scholar 

  37. Wainstein G, Muller EJ, Taylor N, Munn B, Shine JM. The role of the locus coeruleus in shaping adaptive cortical melodies. Trends Cogn Sci. 2022;26(6):527–38.

    Article  PubMed  Google Scholar 

  38. Hermans EJ, van Marle HJ, Ossewaarde L, Henckens MJ, Qin S, van Kesteren MT, et al. Stress-related noradrenergic activity prompts large-scale neural network reconfiguration. Science. 2011;334(6059):1151–3.

    Article  CAS  PubMed  Google Scholar 

  39. Shine JM. Neuromodulatory influences on integration and segregation in the brain. Trends Cogn Sci. 2019;23(7):572–83.

    Article  PubMed  Google Scholar 

  40. Shine JM, Muller EJ, Munn B, Cabral J, Moran RJ, Breakspear M. Computational models link cellular mechanisms of neuromodulation to large-scale neural dynamics. Nat Neurosci. 2021;24(6):765–76.

    Article  CAS  PubMed  Google Scholar 

  41. Shine JM, Aburn MJ, Breakspear M, Poldrack RA. The modulation of neural gain facilitates a transition between functional segregation and integration in the brain. Elife. 2018;7:e31130.

    Article  PubMed  PubMed Central  Google Scholar 

  42. Shine JM, van den Brink RL, Hernaus D, Nieuwenhuis S, Poldrack RA. Catecholaminergic manipulation alters dynamic network topology across cognitive states. Netw Neurosci. 2018;2(3):381–96.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Takakusaki K. Functional neuroanatomy for posture and gait control. J Mov Disord. 2017;10(1):1–17.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Jahn K, Deutschlander A, Stephan T, Kalla R, Hufner K, Wagner J, et al. Supraspinal locomotor control in quadrupeds and humans. Prog Brain Res. 2008;171:353–62.

    Article  PubMed  Google Scholar 

  45. Takakusaki K. Neurophysiology of gait: from the spinal cord to the frontal lobe. Mov Disord. 2013;28(11):1483–91.

    Article  PubMed  Google Scholar 

  46. Gilat M, Dijkstra BW, D’Cruz N, Nieuwboer A, Lewis SJG. Functional MRI to study gait impairment in Parkinson’s disease: a systematic review and exploratory ALE meta-analysis. Curr Neurol Neurosci Rep. 2019;19(8):49.

    Article  PubMed  Google Scholar 

  47. Nonnekes J, Bereau M, Bloem BR. Freezing of gait and its levodopa paradox. JAMA Neurol. 2020;77(3):287–8.

    Article  PubMed  Google Scholar 

  48. Gilat M, Ginis P, Zoetewei D, De Vleeschhauwer J, Hulzinga F, D’Cruz N, et al. A systematic review on exercise and training-based interventions for freezing of gait in Parkinson’s disease. NPJ Parkinson’s Dis. 2021;7(1):81.

    Article  Google Scholar 

  49. Avanzino L, Lagravinese G, Abbruzzese G, Pelosin E. Relationships between gait and emotion in Parkinson’s disease: a narrative review. Gait Posture. 2018;65:57–64.

    Article  PubMed  Google Scholar 

  50. Tosserams A, Weerdesteyn V, Bal T, Bloem BR, Solis-Escalante T, Nonnekes J. Cortical correlates of gait compensation strategies in Parkinson disease. Ann Neurol. 2022;91(3):329–41.

    Article  PubMed  PubMed Central  Google Scholar 

  51. Nieuwhof F, Helmich RC. Entangled cerebral networks in Parkinson’s disease. Brain. 2017;140(11):2767–9.

    Article  PubMed  Google Scholar 

  52. Taylor NL, Wainstein G, Quek D, Lewis SJG, Shine JM, Ehgoetz Martens KA. The contribution of noradrenergic activity to anxiety-induced freezing of gait. Mov Disord. 2022;37(7):1432–43.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Shine JM, Matar E, Ward PB, Frank MJ, Moustafa AA, Pearson M, et al. Freezing of gait in Parkinson’s disease is associated with functional decoupling between the cognitive control network and the basal ganglia. Brain. 2013;136(Pt 12):3671–81.

    Article  PubMed  Google Scholar 

  54. Lewis SJ, Barker RA. A pathophysiological model of freezing of gait in Parkinson’s disease. Parkinsonism Relat Disord. 2009;15(5):333–8.

    Article  PubMed  Google Scholar 

  55. Giguere N, Burke Nanni S, Trudeau LE. On cell loss and selective vulnerability of neuronal populations in Parkinson’s disease. Front Neurol. 2018;9:455.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Oertel WH, Henrich MT, Janzen A, Geibl FF. The locus coeruleus: another vulnerability target in Parkinson’s disease. Mov Disord. 2019;34(10):1423–9.

    Article  PubMed  Google Scholar 

  57. Weinshenker D. Long road to ruin: noradrenergic dysfunction in neurodegenerative disease. Trends Neurosci. 2018;41(4):211–23.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Zarow C, Lyness SA, Mortimer JA, Chui HC. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003;60(3):337–41.

    Article  PubMed  Google Scholar 

  59. Braak H, Del Tredici K. Neuropathological staging of brain pathology in sporadic Parkinson’s disease: separating the wheat from the chaff. J Parkinsons Dis. 2017;7(s1):S71–85.

    Article  PubMed  PubMed Central  Google Scholar 

  60. Halliday G. An evidence base for noradrenergic deficits in Parkinson’s disease. Mov Disord. 2012;27(13):1589–91.

    Article  PubMed  Google Scholar 

  61. Shine JM, O’Callaghan C, Walpola IC, Wainstein G, Taylor N, Aru J, et al. Understanding the effects of serotonin in the brain through its role in the gastrointestinal tract. Brain. 2022;145(9):2967–81.

    Article  PubMed  Google Scholar 

  62. Calabresi P, Picconi B, Parnetti L, Di Filippo M. A convergent model for cognitive dysfunctions in Parkinson’s disease: the critical dopamine–acetylcholine synaptic balance. Lancet Neurol. 2006;5(11):974–83.

    Article  CAS  PubMed  Google Scholar 

  63. Alameda C, Sanabria D, Ciria LF. The brain in flow: a systematic review on the neural basis of the flow state. Cortex. 2022;154:348–64.

    Article  PubMed  Google Scholar 

  64. van der Linden D, Tops M, Bakker AB. The neuroscience of the flow state: involvement of the locus coeruleus norepinephrine system. Front Psychol. 2021;12: 645498.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Cole LW. The relation of strength of stimulus to rate of learning in the chick. J Animal Behav. 1911;1(2):111–24.

    Article  Google Scholar 

  66. Dodson JD. The relation of strength of stimulus to rapidity of habit-formation in the kitten. J Anim Behav. 1915;5:330–6.

    Article  Google Scholar 

  67. Delval A, Moreau C, Bleuse S, Guehl D, Bestaven E, Guillaud E, et al. Gait and attentional performance in freezers under methylphenidate. Gait Posture. 2015;41(2):384–8.

    Article  CAS  PubMed  Google Scholar 

  68. Devos D. Methylphenidate for freezing of gait and attention deficit in parkinsonian patients under subthalamic stimulation (PARKGAIT-II): a randomised placebo-controlled trial. Mov Disord. 2012;1:S113–4.

    Google Scholar 

  69. Fukada K, Endo T, Yokoe M, Hamasaki T, Hazama T, Sakoda S. L-threo-3,4-dihydroxyphenylserine (L-DOPS) co-administered with entacapone improves freezing of gait in Parkinson’s disease. Med Hypotheses. 2013;80(2):209–12.

    Article  CAS  PubMed  Google Scholar 

  70. Kutz C, Adams L, Moncheski E. Effects of droxidopa when measuring gait speed, kyphosis, and functional reach in Parkinson’s disease. Mov Disord. 2018;33(Supplement 2):S1.

    Google Scholar 

  71. Doppler CEJ, Kinnerup MB, Brune C, Farrher E, Betts M, Fedorova TD, et al. Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinson’s disease. Brain. 2021;144(9):2732–44.

    Article  PubMed  Google Scholar 

  72. Prasuhn J, Prasuhn M, Fellbrich A, Strautz R, Lemmer F, Dreischmeier S, et al. Association of locus coeruleus and substantia nigra pathology with cognitive and motor functions in patients with Parkinson disease. Neurology. 2021;97(10):e1007–16.

    Article  CAS  PubMed  Google Scholar 

  73. Betts MJ, Kirilina E, Otaduy MCG, Ivanov D, Acosta-Cabronero J, Callaghan MF, et al. Locus coeruleus imaging as a biomarker for noradrenergic dysfunction in neurodegenerative diseases. Brain. 2019;142(9):2558–71.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Tosserams A, Keijsers N, Kapelle W, Kessels RPC, Weerdesteyn V, Bloem BR, et al. Evaluation of compensation strategies for gait impairment in patients with Parkinson disease. Neurology. 2022;99(20):e2253–63.

    PubMed  PubMed Central  Google Scholar 

  75. Cerri S, Mus L, Blandini F. Parkinson’s disease in women and men: what’s the difference? J Parkinsons Dis. 2019;9(3):501–15.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The Fox Insight Study is funded by The Michael J. Fox Foundation for Parkinson’s Research. We would like to thank the Parkinson’s community for participating in this study to make this research possible. The authors would also like to thank ParkinsonNEXT for facilitating the distribution of the survey in the Netherlands. This study was supported by a ZonMW Veni grant to Jorik Nonnekes (16.196.022), and an Academy Van Leersum grant of the Academy Medical Sciences Fund, Royal Netherlands Academy of Arts & Sciences to Anouk Tosserams. The Center of Expertise for Parkinson & Movement Disorders was supported by a center of excellence grant awarded by the Parkinson Foundation.

Funding

AT was supported by an Academy Van Leersum grant of the Academy Medical Sciences Fund, Royal Netherlands Academy of Arts & Sciences. BRB currently serves as Editor-in-Chief for the Journal of Parkinson’s disease, serves on the editorial board of Practical Neurology and Digital Biomarkers, has received honoraria from serving on the scientific advisory board for the Critical Path Institute, Kyowa Kirin, UCB and Zambon, has received fees for speaking at conferences from AbbVie, Bial, GE Healthcare, Oruen, Roche and Zambon, and has received research support from the Netherlands Organization for Scientific Research, the Michael J Fox Foundation, Nothing Impossible, Parkinson Vereniging, the Parkinson’s Foundation, Hersenstichting Nederland, Verily Life Sciences, Horizon 2020, the Topsector Life Sciences and Health, Abbvie, UCB, Yesse Technologies and Zambon, all outside the submitted work. KAEM was supported by a Parkinson Canada New Investigator grant, as well as a Natural Sciences and Engineering Research Council of Canada Discovery grant. RCH was supported by a research grant (VIDI; #09150172010044) from the Netherlands Organization for Scientific Research. He has acted as consultant for UCB (unrelated to this work). RPCK was partially supported by a grant from the European Regional Development Fund (ERDF/EFRO, grant number PROJ-00928) outside the submitted work. He is associate editor for Neuropsychology Review, member of the editorial board of the Journal of the International Neuropsychological Society, member of the scientific advisor board of Alzheimer Nederland, chair of the scientific advisory board of the Korsakoff Knowledge Center Netherlands (Korsakov Kenniscentrum), and scientific consultant for the University of Michigan. JMS was supported by the National Health and Medical Research Council (1193857). NLT was supported by the Australian Government Research Training Program (RTP) Scholarship. GW reports no disclosures. SJGL was supported by a National Health and Medical Research Council Leadership Fellowship (1195830). JN was supported by a ZonMW Veni grant (16.196.022). He reports a grant from ZonMW (OffRoad grant), Michael J. Fox Foundation, Ipsen Pharmaceuticals and Gossweiler Foundation outside the submitted work.

Author information

Authors and Affiliations

  1. Department of Neurology, Center of Expertise for Parkinson and Movement Disorders, Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands

    Anouk Tosserams, Bastiaan R. Bloem & Rick C. Helmich

  2. Department of Rehabilitation, Center of Expertise for Parkinson and Movement Disorders, Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, PO Box 9101, 6500 HB, Nijmegen, The Netherlands

    Anouk Tosserams & Jorik Nonnekes

  3. Department of Kinesiology and Health Sciences, University of Waterloo, Waterloo, ON, Canada

    Kaylena A. Ehgoetz Martens

  4. Department of Neuropsychology and Rehabilitation Psychology, Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, The Netherlands

    Roy P. C. Kessels

  5. Department of Medical Psychology and Radboudumc Alzheimer Center, Radboud University Medical Centre, Donders Institute for Brain, Cognition and Behaviour, Nijmegen, The Netherlands

    Roy P. C. Kessels

  6. Vincent Van Gogh Institute for Psychiatry, Venray, The Netherlands

    Roy P. C. Kessels

  7. Klimmendaal Rehabilitation Center, Arnhem, The Netherlands

    Roy P. C. Kessels

  8. Brain and Mind Centre, Parkinson’s Disease Research Clinic, School of Medical Sciences, University of Sydney, Camperdown, NSW, Australia

    James M. Shine, Natasha L. Taylor, Gabriel Wainstein & Simon J. G. Lewis

  9. Centre for Complex Systems, The University of Sydney, Camperdown, NSW, Australia

    James M. Shine

  10. Department of Rehabilitation, Sint Maartenskliniek, Nijmegen, The Netherlands

    Jorik Nonnekes

Authors
  1. Anouk Tosserams
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bastiaan R. Bloem
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kaylena A. Ehgoetz Martens
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Rick C. Helmich
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Roy P. C. Kessels
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. James M. Shine
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Natasha L. Taylor
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Gabriel Wainstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Simon J. G. Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jorik Nonnekes
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AT: concept and design of the study, data collection, interpretation of data, drafting the manuscript. BRB: concept and design of the study, interpretation of data, critical revision of the manuscript. KAEM: interpretation of data, critical revision of the manuscript. RCH: interpretation of data, critical revision of the manuscript. RPCK: interpretation of data, critical revision of the manuscript. JMS: interpretation of data, critical revision of the manuscript. NLT: interpretation of data, critical revision of the manuscript. GW: interpretation of data, critical revision of the manuscript. SJGL: interpretation of data, critical revision of the manuscript. JN: concept and design of the study, data collection, interpretation of data, critical revision of the manuscript. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Jorik Nonnekes.

Ethics declarations

Ethics approval and consent to participate

The study was approved by the Institutional Review Board of the Radboud University Medical Center in Nijmegen, the Netherlands (Ref: 2019-5737). Written informed consent was not necessary for this work.

Consent for publication

Not applicable.

Competing interests

The authors report no competing interests.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tosserams, A., Bloem, B.R., Ehgoetz Martens, K.A. et al. Modulating arousal to overcome gait impairments in Parkinson’s disease: how the noradrenergic system may act as a double-edged sword. Transl Neurodegener 12, 15 (2023). https://doi.org/10.1186/s40035-023-00347-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s40035-023-00347-z

Keywords

Translational Neurodegeneration

ISSN: 2047-9158

Contact us